Fulltext

Immunization of Noncolonized Cystic Fibrosis Patients against Pseudomonas aeruginosa

Cryz, Stanley J. ; Wedgwood, Joanna ; Lang, Alois B. ; Ruedeberg, Anna ; Que, J. U. ; Fürer, Emil ; Schaad, Urs B.

In: Journal of Infectious Diseases, 1994, vol. 169, no. 5, p. 1159-1162

Add to personal list
    Title
    • Immunization of Noncolonized Cystic Fibrosis Patients against Pseudomonas aeruginosa
    Author
    • Cryz, Stanley J.. Swiss Serum and Vaccine Institute and Department of Pediatrics, Inselspital, University of Berne, Berne, Switzerland
    • Wedgwood, Joanna. Swiss Serum and Vaccine Institute and Department of Pediatrics, Inselspital, University of Berne, Berne, Switzerland
    • Lang, Alois B.. Swiss Serum and Vaccine Institute and Department of Pediatrics, Inselspital, University of Berne, Berne, Switzerland
    • Ruedeberg, Anna. Swiss Serum and Vaccine Institute and Department of Pediatrics, Inselspital, University of Berne, Berne, Switzerland
    • Que, J. U.. Swiss Serum and Vaccine Institute and Department of Pediatrics, Inselspital, University of Berne, Berne, Switzerland
    • Fürer, Emil. Swiss Serum and Vaccine Institute and Department of Pediatrics, Inselspital, University of Berne, Berne, Switzerland
    • Schaad, Urs B.. Swiss Serum and Vaccine Institute and Department of Pediatrics, Inselspital, University of Berne, Berne, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Journal of Infectious Diseases, 1994, vol. 169, no. 5, p. 1159-1162. The University of Chicago Press
    Other Version
    Classification
    • Health
    OAI-PMH Identifier
    • oai:doc.rero.ch:293143
    Summary
    The long-term safety and immunogenicity of a polyvalent Pseudomonas aeruginosa conjugate vaccine was evaluated in 30 noncolonized cystic fibrosis patients. Four doses were administered over 3 years, and patients were followed for a mean of 38 months. No acute or long-term adverse effects were noted. Immunization engendered a significant antibody response to all vaccine components. A decline in titers during year 3 of observation was associated with a marked rise in the isolation of P. aeruginosa. This organism was isolated repeatedly from the respiratory tract of 4 patients and only once from 7 patients. The remaining patients were repeatedly culture-negative. Only 1 patient showed clinical deterioration associated with multiple isolations of P. aeruginosa